Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Vaccine Recommendations and Guidelines of the ACIP








Storage and Handling of ImmunobiologicsGeneral Best Practice Guidelines for Immunization						Print
																Related Pages
										Printer friendly version [6 pages]
Updates
Most of the 2011 language was removed because this content is now codified and continually updated in the CDC’s Vaccine Storage and Handling Toolkit. This content included Storage Units, Monitoring Storage Temperature, Vaccine Inventory, and Vaccine Transport.
General Principles
Failure to adhere to recommended specifications for storage and handling of immunobiologics can reduce or destroy their potency, resulting in inadequate or no immune response in the recipient. Recommendations in the product package inserts, including methods for reconstitution of the vaccine, should be followed carefully. Maintenance of vaccine quality is the shared responsibility of all handlers of vaccines from the time a vaccine is manufactured until administration. All vaccines should be inspected on delivery and monitored during storage to ensure that the recommended storage temperatures are maintained. Vaccines should continue to be stored at recommended temperatures immediately upon receipt until use. Inadequate vaccine storage also can result in significant costs to replace vaccine inventory.
Storage Temperature
Vaccines licensed for refrigerator storage should be stored at 2°C-8°C (36°F-46°F). Liquid vaccines containing an aluminum adjuvant permanently lose potency when exposed to freezing temperatures. Non-live vaccines that are stored in a liquid state (i.e., non-lyophilized [freeze-dried]) but that do not contain aluminum adjuvants should also generally be kept at refrigerator temperature, although whether or not they lose potency when frozen is not known. Non-live lyophilized vaccines generally do not need to be frozen, but lyophilized varicella-containing vaccines that are recommended to be stored frozen lose potency when exposed to higher temperatures because the viruses degrade more quickly at storage temperatures that are warmer than recommended (Table 7-1). These varicella-containing vaccines also can be prone to losses in sterility if kept too cold, due to increased gas permeability of the rubber vaccine vial (observed with use of dry ice at temperatures below -50°C or -58°F [personal communication, manufacturer]).
**Top of Page
Expiration Dates and Windows
All vaccines have an expiration date determined by the manufacturer that must be observed. Providers should record the vaccine expiration dates and lot numbers on a stock or inventory record for each vaccine vial when a shipment is received. When vaccines are removed from storage, clinicians and other health-care providers should note whether an expiration window exists for vaccine stored at room temperature or at an intermediate temperature. For example, single-component varicella vaccine that is stored frozen must be discarded after 72 hours of storage at refrigerator temperature. Vaccine transport between the storage site and the administration clinic is discouraged unless the cold chain is maintained, and vaccine transport by the patient is particularly discouraged. An expiration window also applies to vaccines that have been reconstituted. For example, after reconstitution, MMR vaccine should be kept at refrigerator temperature and must be administered within 8 hours. Doses of expired vaccines that are administered inadvertently generally should not be counted as valid and should be repeated. Non-live vaccines should generally be repeated as soon as possible. Recombinant zoster vaccine (RZV) should be administered 28 days after the invalid dose, to reduce the burden of adverse reactions which occurs with this vaccine. Live vaccines should be repeated after a 28-day interval from the invalid dose to reduce the risk for interference from interferon on the subsequent doses. For rotavirus vaccines, the repeat dose should be administered after a 28-day interval from the invalid dose or at the maximum age for the vaccine dose (whichever is earlier). See Vaccine Storage and Handling Toolkit for additional information about expiration dates.
Response to Out-of-Range Temperature Reading
An out-of-range temperature reading should prompt immediate action. A plan should be developed ahead of time to address various types of emergencies that might require removal of vaccine from the original storage unit. Transfer of vaccines to a predesignated alternative emergency storage site might be necessary if a temperature problem cannot be resolved immediately (e.g., plugging in an unplugged unit or closing a door that has been left open). It is critical to avoid freezing vaccine during transport (improperly packing vaccine with ice can damage vaccines). Vaccine should be marked “do not use” and moved to the alternate site after verifying that the alternate unit is at the proper temperature. Determinations of vaccine viability in practice include consideration of both time and magnitude of temperature excursions and should be made in consultation with state/local public health departments or the vaccine manufacturer, as one or both of these groups may have additional information based on a broad international perspective. Damage to the immunogenicity of a vaccine exposed to temperatures outside of the recommended range might not be apparent visually. As a general rule, vaccines that have been stored at inappropriate temperatures should not be administered unless public health authorities or the manufacturer determine it is safe and effective to do so. If such vaccines already have been administered, vaccine exposed to inappropriate temperatures that is inadvertently administered should generally be repeated. Non-live vaccines should generally be repeated as soon as possible. Recombinant zoster vaccine (RZV) is neither live nor inactivated: the repeat dose of RZV should be administered 28 days after the invalid dose, to reduce the burden of adverse reactions which occurs with this vaccine.Live vaccines should be repeated after a 28-day interval from the invalid dose to reduce the risk for interference from interferon on the subsequent doses. For rotavirus vaccines, the repeat dose should be administered after a 28-day interval from the invalid dose or at the maximum age for the vaccine dose (whichever is earlier). Clinicians should consult promptly with state or local health departments in these situations. Consultation with CDC is available when necessary.
**Top of Page
TABLE 7-1. Vaccine storage temperature recommendations
Vaccine storage temperature recommendations
Nonlyophilized, aluminum-adjuvanted vaccinesVaccines
Vaccine storage temperature
Diluent storage temperatureDiphtheria-tetanus-containing vaccines (DT, Td) or pertussis-containing vaccines (DTaP, Tdap)
2°C-8°C (36°F-46°F)
Do not freeze
No diluent(a)HepA and HepB
2°C-8°C (36°F-46°F )
Do not freeze
No diluentMenB(b)
2°C-8°C (36°F-46°F )
Do not freeze
No diluentPCV13
2°C-8°C (36°F-46°F )
Do not freeze
No diluentPCV15
2°C-8°C (36°F-46°F)
Do not freeze
No diluentPCV20
2°C-8°C (36°F-46°F)
Do not freeze
No diluentHPV(b)
2°C-8°C (36°F-46°F )
Do not freeze
No diluentNonlyophilized, nonaluminum-adjuvanted vaccinesVaccines
Vaccine storage temperature
Diluent storage temperaturePRP-OMP Hib
2°C-8°C (36°F-46°F )
No diluentIPV(b)
2°C-8°C (36°F-46°F )
No diluentMenACWY(b),(c)
2°C-8°C (36°F-46°F )
No diluentPPSV
2°C-8°C (36°F-46°F )
No diluentIIV(b)
2°C-8°C (36°F-46°F )
No diluentRZV((b)
2°C-8°C (36°F-46°F )
Do not freeze
2°C-8°C (36°F-46°F )
Do not freezeLyophilized (non-varicella) vaccinesVaccines
Vaccine storage temperature
Diluent storage temperaturePRP-T Hib(b)
2°C-8°C (36°F-46°F )(d)
2°C-8°C  (35°F-46°F)
Do not freezeMMR(b)
-50°C-8°C  (-58°F-46°F) (d)
2°C-25°C  (35°F-77°F)
Can be refrigerated or stored at room temperatureDEN4CYD
2°C-8°C (36°F-46°F) Do not freeze
2°C-8°C (36°F-46 °F) Do not freezeVaricella-containing vaccinesVaccines
Vaccine storage temperature
Diluent storage temperatureMMRV(b)
-50°C to -15°C (-58°F-5°F)
2°C-25°C (35°F-77°F)
Can be refrigerated or stored at room temperatureVaricella(b)
-50°C to -15°C (-58°F-5°F)
2°C-25°C (35°F-77°F)
Can be refrigerated or stored at room temperatureNoninjectable vaccinesVaccines
Vaccine storage temperature
Diluent storage temperatureRV5 vaccine(b)
2°C-8°C (36°F-46°F )
Do not freeze
No diluentRV1 vaccine(b)
2°C-8°C (36°F-46°F )
Do not freeze
The diluent may be stored at a controlled room temperature 20°C-25°C (68°F-77°F).
Do not freezeLAIV(b)
2°C-8°C (36°F-46°F )
No diluentShow More
**Abbreviations:** DEN4CYD = dengue vaccine; DT = diphtheria and tetanus toxoids; DTaP = diphtheria and tetanus toxoids and acellular pertussis; HepA = hepatitis A; HepB = hepatitis B; Hib = *Haemophilus influenzae*type b; HPV = human papillomavirus; IIV = inactivated influenza vaccine; IPV = inactivated poliovirus; LAIV = live, attenuated influenza vaccine; MenACWY = quadrivalent meningococcal conjugate vaccine; MenB = Serogroup B meningococcal vaccine; MMR = measles, mumps, and rubella; MMRV = measles, mumps, rubella, and varicella; MPSV4 = quadrivalent meningococcal polysaccharide vaccine; PCV13 = pneumococcal conjugate vaccine; PPSV23= pneumococcal polysaccharide vaccine; PRP-OMP = polyribosylribitol phosphate-meningococcal outer membrane protein conjugate; PRP-T = polyribosylribitol phosphate polysaccharide conjugated to a tetanus toxoid; PRP-T Hib = polyribosylphosphate tetanus-toxoid conjugate Hib vaccine; PRP-T Hib-MenCY = polyribosylphosphate-tetanus-toxoid Hib vaccine with a bivalent Meningococcal vaccine; RV = rotavirus; RV1 = live, attenuated monovalent rotavirus vaccine; RV5 = live, reassortment pentavalent rotavirus vaccine; Td = tetanus and diphtheria toxoids; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis.
**Sources:** (*1,2*).
(a) DTaP-Daptacel is sometimes used as a diluent for ActHib.
(b) Protect from light.
(c) There are 2 meningococcal conjugate vaccines; Menactra is nonlyophilized, and Menveo is lyophilized. Both powder and diluent should be stored at 35°F-46°F.
(d) The lyophilized pellet may be stored at freezer temperature; the reconstituted vaccine should be stored at refrigerator temperature.

References
Kroger A, Atkinson W, Pickering L. General immunization practices. In: Plotkin S, Orenstein W, Offit P, eds. *Vaccines*. 6th ed. China: Elsevier Saunders; 2013:88-111.
MMWR Morb Mortal Wkly Rep. 2003;52(42):1023-1025.**Top of Page
							
					
							Last Reviewed:  January 20, 2023						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeACIP Recs Home
Vaccine-Specific Recommendationsplus icon
Anthrax
Cholera
COVID-19
Dengue
DTaP/IPV/Hib/HepB
DTaP/Tdap/Td
Ebola
Hepatitis A
Hepatitis B
Hib
HPV
Influenza
Japanese Encephalitis
MMR
MMRV
Meningococcal
Pneumococcal
Polio
Rabies
Rotavirus
RSV
Smallpox
TBE
Typhoid
Varicella
Yellow Fever
Zoster (Shingles)
Recs Listed by Date
Comprehensive Recommendations and Guidelinesplus icon
General Best Practice Guidelinesplus icon
Introduction
History
Timing and Spacing of Immunobiologics
Contraindications and Precautions
Preventing and Managing Adverse Reactions
Vaccine Administration
Storage and Handling of Immunobiologics
Altered Immunocompetence
Special Situations
Vaccinations Records
Vaccination Programs
Vaccine Information Sources
Appendix 1: Glossary
Appendix 2: Membership
Archived ACIP Recs
Vaccine Recommendations for Emergency Situations To receive email updates about this page, enter your email address: Email Address			What's this?				Submit
 Vaccines & ImmunizationsVFC ResolutionsACIP Web SiteCDC's International Travelers Yellow BookClinical Travel Notices, Updates, and Vaccine Shortages


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue